Docoh
Loading...

HAE Haemonetics

Haemonetics is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Its technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services.

Company profile

Ticker
HAE
Exchange
CEO
Christopher Simon
Employees
Incorporated
Location
Fiscal year end
SEC CIK
IRS number
42882273

HAE stock data

(
)

Calendar

26 May 21
4 Aug 21
3 Apr 22
Quarter (USD)
Apr 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Apr 21 Mar 20 Mar 19 Mar 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Haemonetics earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 192.31M 192.31M 192.31M 192.31M 192.31M 192.31M
Cash burn (monthly) (positive/no burn) (positive/no burn) 7.06M (positive/no burn) (positive/no burn) (positive/no burn)
Cash used (since last report) n/a n/a 28.52M n/a n/a n/a
Cash remaining n/a n/a 163.79M n/a n/a n/a
Runway (months of cash) n/a n/a 23.2 n/a n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
1 Jul 21 Burke William P. Mr. Common Stock Sell Dispose S No Yes 66.6 4,293 285.91K 30,291
14 Jun 21 Burke William P. Mr. Common Stock Sell Dispose S No No 59.87 190 11.38K 34,584
14 Jun 21 Simon, Christopher Common Stock Sell Dispose S No No 59.87 1,200 71.84K 191,806
14 Jun 21 Basil Michelle L Common Stock Sell Dispose S No No 59.87 195 11.67K 38,410
14 Jun 21 Goldstein Dan Common Stock Sell Dispose S No No 59.87 39 2.33K 4,054

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

96.3% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 292 283 +3.2%
Opened positions 53 54 -1.9%
Closed positions 44 35 +25.7%
Increased positions 99 74 +33.8%
Reduced positions 102 113 -9.7%
13F shares
Current Prev Q Change
Total value 5.44B 5.89B -7.6%
Total shares 49.07M 49.6M -1.1%
Total puts 52.7K 134.9K -60.9%
Total calls 99.8K 120.5K -17.2%
Total put/call ratio 0.5 1.1 -52.8%
Largest owners
Shares Value Change
Capital Research Global Investors 6.22M $690.2M +10.3%
Vanguard 4.88M $542.13M +0.6%
BLK Blackrock 4.8M $532.58M +2.1%
ATAC Neuberger Berman 2.84M $313.85M +0.2%
FMR 2.25M $249.89M -9.4%
BEN Franklin Resources 1.86M $206.78M +3.7%
Wellington Management 1.43M $158.45M +4.6%
Capital World Investors 1.29M $142.94M +8.9%
Renaissance Technologies 1.28M $142.1M -18.8%
STT State Street 1.23M $136.22M +0.5%
Largest transactions
Shares Bought/sold Change
Orbimed Advisors 852K +852K NEW
WFC Wells Fargo & Co. 550.57K -665.47K -54.7%
Capital Research Global Investors 6.22M +579.76K +10.3%
Norges Bank 0 -503.37K EXIT
HealthCor Management 148.48K -417.89K -73.8%
Nitorum Capital 0 -402.1K EXIT
GW&K Investment Management 111 -296.24K -100.0%
Renaissance Technologies 1.28M -296.1K -18.8%
FMR 2.25M -232.57K -9.4%
PFG Principal Financial Group Inc - Registered Shares 380.55K +227.29K +148.3%

Financial report summary

?
Competition
TerumoExactus
Management Discussion
  • Our principal operations are in the United States, Europe, Japan and other parts of Asia. Our products are marketed in approximately 90 countries around the world through a combination of our direct sales force and independent distributors and agents.
  • International sales are generally conducted in local currencies, primarily Japanese Yen, Euro, Chinese Yuan and Australian Dollar. Our results of operations are impacted by changes in foreign exchange rates, particularly in the value of the Yen, Euro and Australian Dollar relative to the U.S. Dollar. We have placed foreign currency hedges to mitigate our exposure to foreign currency fluctuations.
  • Please see the section entitled “Foreign Exchange” in this discussion for a more complete explanation of how foreign currency affects our business and our strategy for managing this exposure.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: Abbott, ablation, absent, ambulatory, anesthesiologist, apparent, appointing, arterial, artery, Article, Attorney, attrition, automatically, awaiting, benchmarked, beneficial, body, bond, Brexit, broadly, cardiac, Cardinal, Cardiva, case, certificate, characterized, Clara, Clinton, coaching, collaboration, collaborative, collagen, complementary, complication, compression, conclusion, consecutive, construction, consummated, content, cooperating, creditor, culture, defend, developmental, diagnose, District, Divesture, earnout, electrophysiology, encounter, encourage, entrant, ethylene, expend, expiry, factually, FDCA, feature, feedback, femoral, filtration, formation, foundation, fundamental, gathering, GPI, guarantee, GVS, halt, HemoAssay, holder, IDE, Importantly, inactive, incidence, incumbent, indenture, infrequent, Inlog, inquiry, insolvency, introduction, investigation, investigational, issuable, Kingdom, leader, leadership, learn, learning, lender, Log, meant, Merger, MVP, necessarily, necessitate, negligent, nomogram, noncompetitive, nonconvertible, nonrecurring, nurse, occurrence, Offshore, omit, oxide, PA, par, payer, peripheral, Persona, perspective, philosophy, preceding, predominantly, premium, propensity, proportion, proposition, proven, read, reading, redeemable, redeemed, redemption, reliant, remeasured, revert, rollforward, Santa, Science, searchable, secondary, shelter, Similarly, simple, stopping, strike, strive, subpoena, survey, Suzhou, takeover, temporarily, Tetakawi, thrive, thromboelastography, thromboelastometry, tied, trial, trustee, Tuition, unsafe, unsecured, unwinding, VASCADE, vein, vessel, viability, vision, workplace, wrongful
Removed: advance, ASR, Behring, biologic, BLA, central, Citibank, confirm, consuming, continuation, couple, database, Directive, discarded, diversification, Doc, dose, double, enhancement, exempt, explicit, failing, freight, HAE, Hemasphere, hematology, inspectional, JMS, Kawasumi, leukoreduced, licensure, meantime, menu, motivate, notably, NYSE, organizational, OrthoPAT, participant, payor, PHSA, placement, predictable, predominately, prepaid, realization, recruitment, reinforce, rent, repay, reposition, requirement, reverse, saving, schedule, SEBRA, span, switching, symbol, transparent, unavailable, uniform, upcoming, web, withdrawn, York

Patents

APP
Utility
Detection of Reversal of an Anticoagulant Using a Clotting Assay
29 Jul 21
In some embodiments, the invention provides methods for detecting the reversal an anticoagulant at a therapeutically relevant amount or higher in a patient, including subjecting a sample of a control blood component (known not to contain the anticoagulant) to a clotting assay in the presence of an ecarin reagent to obtain a control ecarin clotting measurement; subjecting a sample of a control blood component (known not to contain the anticoagulant) to a clotting assay in the presence of a Factor Xa reagent to obtain a control Factor Xa clotting measurement; subjecting a sample of a blood component from a patient suspected to contain a reversal agent to a clotting assay in the presence of the ecarin reagent to obtain a patient ecarin clotting measurement; subjecting a sample of a blood component from the patient suspected to contain the reversal agent to a clotting assay in the presence of the Factor Xa reagent to obtain a patient Factor Xa clotting measurement; and comparing the control ecarin clotting measurement to the patient ecarin clotting measurement and comparing the control Factor Xa clotting measurement to the patient Factor Xa measurement.
GRANT
Utility
Plasmapheresis centrifuge bowl
20 Jul 21
A plasmapheresis bowl for the separation and collection of plasma includes a core and a feed tube that increase the bowl efficiency and reduce foaming within the plasma.
APP
Utility
System and Method for Collecting Plasma
8 Jul 21
A method for collecting plasma includes determining the weight and hematocrit of a donor, and inserting a venous-access device into the donor.
APP
Utility
System and Method for Collecting Plasma
8 Jul 21
A method for collecting plasma includes determining the weight, height, and hematocrit of a donor, and calculating a donor plasma volume and a target plasma collection volume.
APP
Utility
Diagnostic Kit for Viscoelastic Analysis and Uses and Methods Thereof
20 May 21
A diagnostic kit for viscoelastic analysis of a sample includes a pipette tip containing constituent (A) and a measurement cup containing constituent (B), wherein the constituents (A) and (B) are adapted to form a diagnostic composition upon combination, wherein the diagnostic composition includes an activator of coagulation and a calcium salt.